https://www.businesswire.com/news/home/20241203883795/en/Switch-Therapeutics-Appoints-David-M.-Holtzman-M.D.-to-Its-Scientific-Advisory-Board-and-Announces-Its-First-Development-Candidate-CASi-APOE-a-Liver-Sparing-APOE-RNAi-Therapy
Switch Therapeutics Appoints David M. Holtzman, M.D., to Its Scientific Advisory Board and...
Switch Therapeutics appoints David M. Holtzman, M.D., to Scientific Advisory Board and announces first development candidate, CASi-APOE
david m holtzman